Panobinostat (LBH589)

Name: Panobinostat (LBH589)
Brand: Selleck Chemicals
SKU: S1030
Rating: 5 (279 reviews)

For research use only.

Catalog No.S1030 Synonyms: NVP-LBH589

279 publications

Panobinostat (LBH589) Chemical Structure

CAS No. 404950-80-7

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.

Selleck's Panobinostat (LBH589) has been cited by 279 publications

Cell, 2020, S0092-8674(20)31394-5

PubMed: 33147445 ( click the link to review the publication )

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 36(5):528-544

PubMed: 31631026 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):782-797

PubMed: 31085178 ( click the link to review the publication )

Nat Immunol, 2019, 20(7):835-851

PubMed: 31160797 ( click the link to review the publication )

Nat Med, 2018, 24(11):1752-1761

PubMed: 30349086 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Nat Genet, 2018, 50(10):1442-1451

PubMed: 30224647 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cell, 2014, 20;159(5):1110-1125.

PubMed: 25416949 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Blood, 2020, 10.1182/blood.2019004332

PubMed: 32844992 ( click the link to review the publication )

Nat Commun, 2020, 11(1):583

PubMed: 31996670 ( click the link to review the publication )

Sci Immunol, 2020, 5(50):eabb5168

PubMed: 32826342 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33046

PubMed: 32599665 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 9;39(1):105

PubMed: 32517809 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )
Cancers (Basel), 2020, 5;12(6):E1478

PubMed: 32517016 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2857

PubMed: 33023028 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2903

PubMed: 33050470 ( click the link to review the publication )

PLoS Pathog, 2020, 16(3):e1008442

PubMed: 32196533 ( click the link to review the publication )

Mol Ther Oncolytics, 2020, 18:623-630

PubMed: 33005729 ( click the link to review the publication )

Cells, 2020, 9(2)

PubMed: 32059481 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(6):1827-1843

PubMed: 32642294 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:296

PubMed: 32195191 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(21)E8300

PubMed: 33167494 ( click the link to review the publication )

Sci Rep, 2020, 10(1):3470

PubMed: 32103105 ( click the link to review the publication )

Fluids Barriers CNS, 2020, 2;17(1):37

PubMed: 32487241 ( click the link to review the publication )

Sci China Life Sci, 2020, 10.1007/s11427-020-1736-5

PubMed: 32737855 ( click the link to review the publication )

Exp Hematol, 2020, 81:32-41

PubMed: 31954171 ( click the link to review the publication )

J Thromb Haemost, 2020, 10.1111/jth.15012

PubMed: 32662223 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04021-y

PubMed: 31894347 ( click the link to review the publication )

Blood Adv, 2020, 4(18):4393-4405

PubMed: 32926125 ( click the link to review the publication )

Cancer Lett, 2020, S0304-3835(20)30652-2

PubMed: 33279621 ( click the link to review the publication )

EBioMedicine, 2020, 102853

PubMed: 32654992 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01408-7

PubMed: 32733069 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01191-y

PubMed: 33250513 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:4429-4439

PubMed: 32606937 ( click the link to review the publication )

Cancer Cell, 2020, 38(1):44-59.e9

PubMed: 32663469 ( click the link to review the publication )
Commun Biol, 2020, 3(1):363

PubMed: 32647372 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

J Med Chem, 2020, 10.1021/acs.jmedchem.9b01888

PubMed: 32803970 ( click the link to review the publication )

Cancer Immunol Res, 2020, 8(6):794-805

PubMed: 32213626 ( click the link to review the publication )

Cell Res, 2019, 29(4):286-304

PubMed: 30631154 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3319

PubMed: 31346162 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0525-6

PubMed: 31358854 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(26):12986-12995

PubMed: 31182587 ( click the link to review the publication )

Neuro Oncol, 2019, 10.1093/neuonc/noz215

PubMed: 31711240 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2947-2961

PubMed: 30987999 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Clin Infect Dis, 2019, 10.1093/cid/ciz108

PubMed: 30753360 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Theranostics, 2019, 9(9):2526-2540

PubMed: 31131051 ( click the link to review the publication )

Cell Rep, 2019, 29(9):2783-2795

PubMed: 31775045 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):185

PubMed: 31053152 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

PLoS Pathog, 2019, 15(8):e1007991

PubMed: 31425551 ( click the link to review the publication )
Breast Cancer Res, 2019, 21(1):134

PubMed: 31801577 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):185-195

PubMed: 30301863 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Oncologist, 2019, 24(8):e740-e748

PubMed: 30696721 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2019, 1865(6):1666-1676

PubMed: 30954557 ( click the link to review the publication )

J Biomed Nanotechnol, 2019, 15(5):979-992

PubMed: 30890229 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Biomolecules, 2019, 9(5)

PubMed: 31083537 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18970-18984

PubMed: 30916359 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

J Virol, 2019, 93(24)

PubMed: 31578289 ( click the link to review the publication )

Antimicrob Agents Chemother, 2019, 63(2)

PubMed: 30455231 ( click the link to review the publication )

Epigenetics Chromatin, 2019, 12(1):18

PubMed: 30871586 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )

Mol Carcinog, 2019, 58(12):2230-2240

PubMed: 31478563 ( click the link to review the publication )

Mol Carcinog, 2019, 58(2):234-246

PubMed: 30303565 ( click the link to review the publication )
Virus Res, 2019, 269:197631

PubMed: 31136823 ( click the link to review the publication )

Mol Genet Genomic Med, 2019, 7(5):e613

PubMed: 30891950 ( click the link to review the publication )

Childs Nerv Syst, 2019, 35(5):823-831

PubMed: 30815722 ( click the link to review the publication )

J Nanobiotechnology, 2019, 17(1):69

PubMed: 31113488 ( click the link to review the publication )

J Virus Erad, 2019, 5(3):133-137

PubMed: 31700655 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4866

PubMed: 30451831 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(1):120-129.

PubMed: 29066507 ( click the link to review the publication )

Cancer Res, 2018, 78(5):1155-1168

PubMed: 29259009 ( click the link to review the publication )

Cancer Res, 2018, 78(14):4007-4021

PubMed: 29760046 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Oncogene, 2018, 37(50):6414-6424

PubMed: 30068939 ( click the link to review the publication )

Oncogene, 2018, 37(6):722-731

PubMed: 29059175 ( click the link to review the publication )

Cancer Lett, 2018, 417:152-160

PubMed: 29306016 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):381-392

PubMed: 28839000 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1705-1716

PubMed: 29748211 ( click the link to review the publication )

Cell Oncol (Dordr), 2018, 41(2):201-212

PubMed: 29260509 ( click the link to review the publication )

J Immunol, 2018, 201(3):1086-1096

PubMed: 29914885 ( click the link to review the publication )

J Virol, 2018, 92(13)

PubMed: 29643247 ( click the link to review the publication )
J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9472

PubMed: 29930256 ( click the link to review the publication )

J Proteome Res, 2018, 17(4):1436-1451

PubMed: 29564889 ( click the link to review the publication )

Biomed Pharmacother, 2018, 100:509-520

PubMed: 29494986 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

J Ethnopharmacol, 2018, 211:267-277

PubMed: 28970153 ( click the link to review the publication )

Exp Cell Res, 2018, 363(2):196-207

PubMed: 29317217 ( click the link to review the publication )

PLoS One, 2018, 13(12):e0208147

PubMed: 30592723 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Dis Markers, 2018, 2018:3810108

PubMed: 30647797 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(1):61-74

PubMed: 29049036 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36530-36541

PubMed: 30559935 ( click the link to review the publication )

Oncotarget, 2018, 9(5):6450-6462

PubMed: 29464084 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28586-28598

PubMed: 29983882 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 100(1):174-187

PubMed: 29107335 ( click the link to review the publication )

JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )

Nat Commun, 2017, 8(1):728

PubMed: 28959017 ( click the link to review the publication )

Cancer Res, 2017, 77(11):3027-3039

PubMed: 28363998 ( click the link to review the publication )
Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

Stem Cell Reports, 2017,

PubMed: 29033304 ( click the link to review the publication )

Cell Death Dis, 2017,

PubMed: 29022919 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Arch Toxicol, 2017, 91(1):365-391

PubMed: 27015953 ( click the link to review the publication )

Arch Toxicol, 2017, 91(2):839-864

PubMed: 27188386 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Br J Haematol, 2017, 178(5):728-738

PubMed: 28480959 ( click the link to review the publication )

Epigenetics, 2017, 12(2):105-112

PubMed: 27935420 ( click the link to review the publication )

Int J Nanomedicine, 2017, 12:1385-1399

PubMed: 28260886 ( click the link to review the publication )

J Biol Chem, 2017, 292(9):3683-3691

PubMed: 28087699 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

J Neuropathol Exp Neurol, 2017,

PubMed: 29136455 ( click the link to review the publication )

Exp Cell Res, 2017, 350(1):218-225

PubMed: 27914787 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):42-50

PubMed: 28107750 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169485

PubMed: 28052119 ( click the link to review the publication )

Horm Cancer, 2017, 8(4):257-267

PubMed: 28516379 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Blood Adv, 2017, 1(19):1575-1583

PubMed: 29296798 ( click the link to review the publication )

Oncotarget, 2017, 8(50):87307-87316

PubMed: 29152082 ( click the link to review the publication )
Genom Data, 2017, 12:14-16

PubMed: 28239551 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17833-17848

PubMed: 28147319 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3908-3921

PubMed: 29423093 ( click the link to review the publication )

Oncotarget, 2017, 8(18):30019-30029

PubMed: 28415789 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56747-56757

PubMed: 28915627 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94569-94579

PubMed: 29212250 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:127-148

PubMed: 27761818 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(3):1159-1176

PubMed: 28180300 ( click the link to review the publication )

EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(10):2534-44

PubMed: 26733615 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(46):13162-13167

PubMed: 27799547 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Oncogene, 2016, 35(46):6026-6037

PubMed: 27157610 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Mol Oncol, 2016, 10(5):735-750

PubMed: 26775640 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2016, 3:16003

PubMed: 27626039 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(10):2685-2692

PubMed: 27459069 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

J Cell Physiol, 2016, 231(3):650-8

PubMed: 26218437 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )
Sci Rep, 2016, 6:30749

PubMed: 27480951 ( click the link to review the publication )

J Biol Chem, 2016, 291(16):8745-55

PubMed: 26912657 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:1393-1405

PubMed: 27802904 ( click the link to review the publication )

Retrovirology, 2016, 13(1):36

PubMed: 27206407 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Am J Transl Res, 2016, 8(9):3893-3902

PubMed: 27725868 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0148912

PubMed: 26859414 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(11):2644-52

PubMed: 26980288 ( click the link to review the publication )

J Org Chem, 2016, 81(22):11324-11334

PubMed: 27768313 ( click the link to review the publication )

JCI Insight, 2016, 1(5):e85061

PubMed: 27699258 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27769045 ( click the link to review the publication )

Ann Rheum Dis, 2015, 10.1136/annrheumdis-2014-206258

PubMed: 25589513 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

Biomaterials, 2015, 73:110-9

PubMed: 26406451 ( click the link to review the publication )

Cancer Res, 2015,

PubMed: 26294211 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Arch Toxicol, 2015, 89(9):1599-618

PubMed: 26272509 ( click the link to review the publication )

Mol Oncol, 2015, 9(7):1447-1457

PubMed: 25957812 ( click the link to review the publication )

Mol Pharm, 2015, 12(7):2469-76

PubMed: 26030093 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )
J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29478-92

PubMed: 26491017 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074.jbc.M114.624361

PubMed: 25737447 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(12):1784-93

PubMed: 26529495 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2015, 5(3):117-26

PubMed: 26199860 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0126566

PubMed: 26176219 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134426

PubMed: 26247786 ( click the link to review the publication )

Pediatr Blood Cancer, 2015, 62(1):52-9

PubMed: 25308916 ( click the link to review the publication )

Exp Hematol, 2015, 43(6):448-61

PubMed: 25704054 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17698-712

PubMed: 25989842 ( click the link to review the publication )

Western University, 2015, Western University

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(25):21507-21

PubMed: 26087189 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2088-100

PubMed: 25576920 ( click the link to review the publication )

Cancer Lett, 2014, 356(2 Pt B):656-68

PubMed: 25458954 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Anal Chem, 2014, 86(10):4642-7

PubMed: 24559101 ( click the link to review the publication )

Br J Cancer, 2014, 111(2):281-91

PubMed: 24946002 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Immunol, 2014, 193(3):1333-43

PubMed: 24973453 ( click the link to review the publication )

Mol Carcinog, 2014, 53(9):722-35

PubMed: 23475695 ( click the link to review the publication )

BMC Cancer, 2014, 14:17

PubMed: 24418474 ( click the link to review the publication )
PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):649-54

PubMed: 25193706 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Leukemia, 2013, 27(6):1291-300

PubMed: 23411464 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Cancer Lett, 2013, 329(1):17-26

PubMed: 22995071 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R58

PubMed: 23879992 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Stem Cells, 2013, 31(7):1434-45

PubMed: 23592435 ( click the link to review the publication )

Br J Haematol, 2013, 162(4):559-62

PubMed: 23692150 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):429-33

PubMed: 23932191 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1507-14

PubMed: 23824064 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1325-34

PubMed: 23515752 ( click the link to review the publication )

PLoS One, 2013, 8(8):e74253

PubMed: 23991216 ( click the link to review the publication )

PLoS One, 2013, 8(11):e79106

PubMed: 24244429 ( click the link to review the publication )

PLoS One, 2013, 8(9):e76662

PubMed: 24098799 ( click the link to review the publication )

PLoS One, 2013, 8(7):e69992

PubMed: 23922886 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )
Theriogenology, 2013, 80(6):630-5

PubMed: 23866857 ( click the link to review the publication )

Protein Expr Purif, 2013, 92(1):119-127

PubMed: 24056254 ( click the link to review the publication )

Genet Mol Res, 2013, 12(4):5405-13

PubMed: 24301913 ( click the link to review the publication )

The University of Western Ontario, 2013, CHAE YOUNG HAN

PubMed: ( click the link to review the publication )

Obstet Gynecol Int, 2013, 2013:828165

PubMed: 24381593 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Blood, 2012, 119(6):1450-8

PubMed: 22144178 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 131(3):777-89

PubMed: 21452019 ( click the link to review the publication )

J Neurooncol, 2012, 110(3):335-48

PubMed: 23054560 ( click the link to review the publication )

Acta Neuropathol, 2011, 122(5):637-50

PubMed: 21863243 ( click the link to review the publication )

PLoS One, 2011, 6(6):e20920

PubMed: 21687633 ( click the link to review the publication )

PLoS One, 2011, 6(2):e17138

PubMed: 21359182 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Biochem Bioph Res Co, 2010, 391(4):1748-51

PubMed: 20043870 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Targets

HDAC (MOLT-4 cells) ^[1]	HDAC (Reh cells) ^[1]
5 nM	20 nM

In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. ^[1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT29	MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnqdW0xNTFyIN88US=>	MlTuNE01KGR?		MVPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MmTJNlY4ODJ5OES=
HepG2	MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3[2SFAuOTBizszN	MWqwMVQh\A>?		M3rLUIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	Ml7INlY4ODJ5OES=
HT29	M{L6cmZ2dmO2aX;uJGF{e2G7	M4PW[lUxyqCwTR?=	NH\wXnczPC15MjDo		M3K0VIlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhPDkEoHlCpC=>	M124VVI3PzB{N{i0
HepG2	NHPoSpFHfW6ldHnvckBCe3OjeR?=	NHXIWJQ2OMLibl2=	M1WwVFI1NTd{IHi=		M{[zdYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhOjUEoHlCpC=>	M4XzR\|I3PzB{N{i0
HCC827	NEHYRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXW1M\|cvPS9zMDDuUS=>	MkS3O\|LDqGh?	MmD1SG1UVw>?	MlTJ[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ?	M4fHeFI3Pjd3NEi0
A549	NGTsO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPtNVAwOTVxMkCgcm0>	M3HBXlczyqCq	M4nHR2ROW09?	NEHq[o5mdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?=	MYGyOlY4PTR6NB?=
NCI-H460	NGT4UWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fhelExNzJyL{OwJI5O	NFjITlU4OsLiaB?=	MnTDSG1UVw>?	NVf5XJM1\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK=	M1PSflI3Pjd3NEi0
J89GFP	NYKweHlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4j3N2ROW00EoB?=	NVTXO3pwTUN3ME20PU45PSEEsTCxNk43PSCwTR?=	M2fMT\|I3PTZ\|NU[4
THP89GFP	MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoTOSG1UV8Li	M4n2XmVEPTB;MUmuN\|QhyrFiNj60N{BvVQ>?	NITHV4UzPjV4M{W2PC=>
SK-NEP-1	NVOyUZBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX2wMlAy6oDVMUCuNEDPxE1?	MmiyNlQhcA>?	NFPHZ2hFVVORwrC=	MUHJR\|UxRTd4LkO0JI5O	NYf2eItEOjZzN{[yNVk>
G401	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TGS\|AvODIkgKOxNE4xKM7:TR?=	Mnr6NlQhcA>?	MXnEUXNQyqB?	M1zISGlEPTB;MUSzMlAzKG6P	NWTuO4pUOjZzN{[yNVk>
SK-NEP-1	M3\USGNmdGxiVnnhZoltcXS7IFHzd4F6	MkPyOVAhdk1?	M3m0VFHjiJN2IHS=	M2n2dmROW00EoB?=	NFjsRZZz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ?	NVrkVYZuOjZzN{[yNVk>
G401	NGP1fXdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3vqVFUxKG6P	NFi3OY0y6oDVNDDk	Mmj4SG1UV8Li	MUDy[YR2[2W\|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	MlPDNlYyPzZ{MUm=
SK-NEP-1	M3izPGFxd3C2b4Ppd{BCe3OjeR?=	M{jnVVUxNzFyMDDuUS=>	NVjzPW5vOjRiaB?=	MkfxSG1UV8Li	MUPpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MUeyOlE4PjJzOR?=
G401	M4XobGFxd3C2b4Ppd{BCe3OjeR?=	NETQTmk2OC9zMECgcm0>	NX3wbmpNOjRiaB?=	NVm0PZg6TE2VT9Mg	M3myNYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MXSyOlE4PjJzOR?=
SK-NEP-1	M374e2Z2dmO2aX;uJGF{e2G7	MnHsOVAwOTByIH7N	NIDsO\|YzPCCq	NHrOOIZFVVORwrC=	NI\BNIl{cG:5czD0bIUhcW6mdXP0bY9vKG:oIFTORUBnemGpbXXueIF1cW:w	MX2yOlE4PjJzOR?=
G401	MV3GeY5kfGmxbjDBd5NigQ>?	M3ricFUxNzFyMDDuUS=>	MlT0NlQhcA>?	M2LLWmROW00EoB?=	M1W4RpNpd3e\|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25?	NV7Qc4dTOjZzN{[yNVk>
SK-NEP-1	NYjOdZFqTnWwY4Tpc44hSXO\|YYm=	NW\NUodIPTBxMUCwJI5O	Mlr5NlQhcA>?	MmS3SG1UV8Li	NGDBT4dqdmS3Y3XzJINmdGxiY4njcIUh\Gm\|b4Lk[ZLDqA>?	NF;mPGczPjF5NkKxPS=>
G401	MXXGeY5kfGmxbjDBd5NigQ>?	MYW1NE8yODBibl2=	MUKyOEBp	MlT3SG1UV8Li	MnrlbY5lfWOnczDj[YxtKGO7Y3zlJIRqe2:{ZHXyxsA>	NGHvc5YzPjF5NkKxPS=>
RPMI 8226	MX;D[YxtKFO3co\peoFtKEG\|c3H5	NEH4VYMzNzRxNjDuUS=>	NXXFelJIPDkkgJno		NEDNXW1qdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq	MX[yOlAxODJ7Mh?=
OPM2	M3SzcGNmdGxiU4Xyeol3[WxiQYPzZZk>	M4\XSFIwPC94IH7N	MnTxOFjjiImq		NUHZbmt2cW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?=	NIOzR3ozPjByMEK5Ni=>
U266	NXLFR\|FVS2WubDDTeZJ3cX[jbDDBd5NigQ>?	NWHGOGk1Oi92L{[gcm0>	MXW0PQKBkWh?		MVnpcoR2[2W\|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp	M4PYNVI3ODByMkmy
H929	NFv0dVJE\WyuIGP1dpZqfmGuIFHzd4F6	NH7tXpEzNzRxNjDuUS=>	NYrofVFvPDkkgJno		NUf1SYljcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?=	NXHQN2t1OjZyMECyPVI>
RPMI 8226	M4PLO2Fxd3C2b4Ppd{BCe3OjeR?=	M3[3N\|TjiImwTR?=	NHfHUm0zPC92ODDo		NHPiW4NqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	NV\VcGE{OjZyMECyPVI>
HCC827	M2faUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkC1NVAhdk1?	NGDhbJM1QCCq	M1;LRmROW09?	M{nEd4VvcGGwY3XzJINqe3CuYYTpckB{\W6\|aYTpeol1gcLi	M4HEOlI2QTR2NkG3
NCI-H23	Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoftNVAhdk1?	NF7sXm41QCCq	MUPEUXNQ	MUPlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>?	Ml3iNlU6PDR4MUe=
AML3	NUXQO3IzTnWwY4Tpc44hSXO\|YYm=	Mlq4NE0yKM7:TR?=	NFzwfFAzPMLiaB?=		Mk\pbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NUTRSZJ4OjV4MUK5OFE>
ML-1	NV;OWJNoTnWwY4Tpc44hSXO\|YYm=	NXrkRm5bOC1zIN88US=>	M{TFRlI1yqCq		NY[4O2NjcW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NFjKfo8zPTZzMkm0NS=>
RPMI-8226vr10	MmjrSpVv[3Srb36gRZN{[Xl?	MnLpNE0yKM7:TR?=	M3q4XVI1yqCq		NHrkUGFqdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NFu1XJIzPTZzMkm0NS=>
ML-1	MlPwSpVv[3Srb36gRZN{[Xl?	NH;WWnIyKM7:TR?=	M1fidlI1yqCq		MkDubY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUA1NW[xbHS=	MleyNlU3OTJ7NEG=
RPMI-8226vr10	M1;CUmZ2dmO2aX;uJGF{e2G7	NYDCfJFxOSEQvF2=	NF;pRY8zPMLiaB?=		MlzobY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUAzNjVvZn;s[C=>	NYDHNldtOjV4MUK5OFE>
SK-N-BE (2)	NWjzcJB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkPhNlTjiImq		MnL3TWM2OD1zMESuNQKBkcLz4pEJO{45KG6P	MmP3NlU{ODh7MU[=
SK-N-BE (2), PAN MK	MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIWxNJUzPOLCiXi=		MYDJR\|UxRTFyND6w5qCKyrIkgJm3Mlghdk1?	MUCyOVMxQDlzNh?=
SK-N-BE (2), MK PAN	Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmfZNlTjiImq		NY\DSnZwUUN3ME2zPFIvOOLCidMx5qCKPDNwMjDuUS=>	NYLCTWpnOjV\|MEi5NVY>
SK-N-AS	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUDWSJdpOjUkgJno		NXnPOWtjUUN3ME2zO{4y6oDLwsJihKkzNjRibl2=	NWOx[ZF3OjV\|MEi5NVY>
SK-N-DZ	NVrrO5hwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX;tdmdnOjUkgJno		MWXJR\|UxRTF5LkJihKnDueLCiUCuOEBvVQ>?	MYSyOVMxQDlzNh?=
Caki-1	Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIG0dFcyOC9{NT:1NEBvVQ>?	MUC0PEBp		MlvBbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{	MmnlNlUzPzlzOUG=
ACHN	M{C1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY[xNE8zPS93MDDuUS=>	Mn22OFghcA>?		MX\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ?	MX2yOVI4QTF7MR?=
769-P	MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HKPVExNzJ3L{WwJI5O	MXm0PEBp		MnSxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{	MlnWNlUzPzlzOUG=
786-O	NYfHOI9qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXocVIyOC9{NT:1NEBvVQ>?	M1\tZVQ5KGh?		MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ?	NViySItkOjV{N{mxPVE>
Caki-1	NHXUcohCeG:ydH;zbZMhSXO\|YYm=	NV\sWXVzPTBibl2=	Ml25OFghcA>?		NXm0V5hZcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK=	NGnsNYszPTJ5OUG5NS=>
ACHN	NI\0XGlCeG:ydH;zbZMhSXO\|YYm=	MWG1NEBvVQ>?	NEDxUFc1QCCq		NGH6c\|FqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	M1G2OFI2Ojd7MUmx
769-P	M{TmcWFxd3C2b4Ppd{BCe3OjeR?=	Mn:zOVAhdk1?	NGL6ZXI1QCCq		NGDq[GRqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	Mn3INlUzPzlzOUG=
786-O	MoDRRZBweHSxc3nzJGF{e2G7	Mn[zOVAhdk1?	NYX2VGZZPDhiaB?=		NU\kU4RkcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK=	MYKyOVI4QTF7MR?=
Caki-1	NXP4R4tPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TDVlI2NzVyIH7N	MnrxOFghcA>?	NHjVbnBFVVOR	MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk	MYCyOVE4PjN3NB?=
ACHN	M3TFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2r1dVI2NzVyIH7N	Mn7uOFghcA>?	M3rqUWROW09?	NILtU4hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni	MmjMNlUyPzZ\|NUS=
769-P	NEnP[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PleVI2NzVyIH7N	NYTsU4FSPDhiaB?=	MoHLSG1UVw>?	M3XjVolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK=	M17x[VI2OTd4M{W0
Caki-1	MV3Dc4xwdnliRn;ycYF1cW:wIFHzd4F6	M4DpclUxKG6P	MVm3MVE1KGR?	NIDQNGRFVVOR	NXL6VlNpe3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB?	MmftNlUyPzZ\|NUS=
ACHN	MUfDc4xwdnliRn;ycYF1cW:wIFHzd4F6	NXfaO21pPTBibl2=	MX63MVE1KGR?	MkXhSG1UVw>?	NF\4NW5{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>?	NYjIcYZkOjVzN{[zOVQ>
769-P	NFTLdHVEd2yxbomgSo9zdWG2aX;uJGF{e2G7	MWq1NEBvVQ>?	M3\SVFcuOTRiZB?=	M{DEZWROW09?	MUjzeZBxemW\|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=>	MnXrNlUyPzZ\|NUS=
Caki-1	NIHtWFhCeG:ydH;zbZMhSXO\|YYm=	NUfzT5JVPTBibl2=	M3KzWFQ5KGh?	M1zzZ2ROW09?	NH7kRYtqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NWe2OYJtOjVzN{[zOVQ>
ACHN	MWPBdI9xfG:\|aYOgRZN{[Xl?	MWC1NEBvVQ>?	NIPwTYE1QCCq	MYLEUXNQ	MlG5bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MkfKNlUyPzZ\|NUS=
769-P	M{SzR2Fxd3C2b4Ppd{BCe3OjeR?=	NF;jdHY2OCCwTR?=	M4TFblQ5KGh?	NEXidFNFVVOR	MkmybY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NH2wPZQzPTF5NkO1OC=>
MDA-MB-231	NH;TcWlOd3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl?	M{\EOlExyqCwTR?=	MljaN:Kh\A>?	MW\EUXNQ	MU\hcJRmenNiY3XscEBud3KyaH;sc4d6yqB?	M{HM[\|I1QDFyNEm3
BT-549	MnPYUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6	NXn1fm1IOTEEoH7N	NXLVZ4hkO8LiZB?=	M1jBWWROW09?	NFey[4hidHSncoOgZ4VtdCCvb4LwbI9td2e7wrC=	M4\vOlI1QDFyNEm3
MCF-7	NUXqWZl3VW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7	MXWxNOKhdk1?	Mn7pN:Kh\A>?	MXPEUXNQ	MVrhcJRmenNiY3XscEBud3KyaH;sc4d6yqB?	M3fnOVI1QDFyNEm3
MCF-7	NULSV\|ZvTnWwY4Tpc44hSXO\|YYm=	M{LQdFUuPTBibl2=	MYSyOEBp	NIDJRpJFVVOR	M2jxOJJm\HWlZXSgeIhmKGyndnXsJI9nKGW6cILld5Nqd25ib3[gSXLPuSxiUGKgZY5lKE[xeFGxxsA>	MlO2NlQ{PjZ2MEe=
CTS	NGnMR2FCeG:ydH;zbZMhSXO\|YYm=	M1LFd\|DjiJN2MDDuUeKh	NGKyeIM1QCCq		MXTpcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	Mnq4NlQzPDR2Mkm=
OCI-AML3	M1;CS2Fxd3C2b4Ppd{BCe3OjeR?=	M1rsbFDjiJN2MDDuUeKh	MXm0PEBp		NFeyUmJqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	M3e2fVI1OjR2NEK5
U937	MWDBdI9xfG:\|aYOgRZN{[Xl?	MV2w5qCUPDBibl5CpC=>	MWe0PEBp		M1;ZO4lv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M{XIVlI1OjR2NEK5
PC3	MXLBdI9xfG:\|aYOgRZN{[Xl?	MYqwMVExOCCwTR?=	M3zwRVI1NzR6IHi=		MkW5bY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NE\wV\|YzPDF4M{KzNC=>
PC3-AR	NFvsWGtCeG:ydH;zbZMhSXO\|YYm=	M{LMNFAuOTByIH7N	Mor5NlQwPDhiaB?=		MUPpcoR2[2W\|IHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M3HOeVI1OTZ\|MkOw
PC3	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYm3RmdiOC1zMECgcm0>	M3q5[\|I1NzR6IHi=		M13oZ4lv\HWlZYOgZYNkfW23bHH0bY9vKG:oIIP1ZmcyKHCxcIXsZZRqd25?	M{\lO\|I1OTZ\|MkOw
PC3-AR	M4\tV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPNTFIxNTFyMDDuUS=>	NEDFZpIzPC92ODDo		NETCVndqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKHSqZTDHNm0heGijc3W=	M4rkcFI1OTZ\|MkOw
PC3	Ml\ISpVv[3Srb36gRZN{[Xl?	MoLTNE0yODBibl2=	NFzadlAzPCCq		MX;zeZBxemW\|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?=	MlLlNlQyPjN{M{C=
PC3-AR	MofWSpVv[3Srb36gRZN{[Xl?	Ml7QNE0yODBibl2=	NULMcGhEOjRiaB?=		NIjWTox{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM\|IheHKxdHXpci=>	NFHUTm8zPDF4M{KzNC=>
OS-RC-2	Mk\xR4VtdCCYaXHibYxqfHliQYPzZZk>	MXKwMVExODBibl2=	MXeyOE81QC95MjDo	NE\TNIxFVVOR	MYnk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M1n6dVI1OTR2N{O3
OS-RC-2	NHPaPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHBb3o2OCCwTR?=	MUK0PEBp	MYLEUXNQ	NGjtOWNqdmS3Y3XzJGczN01iYYLy[ZN1	NFXU[5EzPDF2NEezOy=>
OS-RC-2	MWPBdI9xfG:\|aYOgRZN{[Xl?	MljBOVAhdk1?	M3vF[VQ5KGh?	NYnKPZNlTE2VTx?=	M2PLO4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	M{Xj[lI1OTR2N{O3
SK-N-AS	M{DneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTzO3JJOOLCk{iwJI5O	MYq0PEBp		NV;YWVNnUUN3ME2yO{41KG6P	MYWyOFA6QDd7OR?=
SK-N-DZ	MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTVcIJ4OOLCk{iwJI5O	NVPGfI1bPDhiaB?=		NYrYbJdpUUN3ME2yNU46KG6P	NYS4eVRZOjRyOUi3PVk>
SK-N-SH	M3H6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLKNQKBmzhyIH7N	NUXIZZM5PDhiaB?=		MkfNTWM2OD15Mj6zJI5O	NWC2RZh7OjRyOUi3PVk>
SK-N-BE	NUfLOZY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnqNQKBmzhyIH7N	MXm0PEBp		MYrJR\|UxRTd3LkSgcm0>	M4rnWlI1ODl6N{m5
SK-N-AS	Mn7nRZBweHSxc3nzJGF{e2G7	NHjjUVAx6oDVOECgcm0>	NWKxd3psPDhiaB?=		MorNdI91\W62bImgbY5lfWOnZDDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	MV6yOFA6QDd7OR?=
SK-N-DZ	NFrp[VJCeG:ydH;zbZMhSXO\|YYm=	NF7rNXkx6oDVOECgcm0>	M37pflQ5KGh?		NVTHfYxOeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v	NHfNUHgzPDB7OEe5PS=>
SK-N-SH	NYP5TmVUSXCxcITvd4l{KEG\|c3H5	MUWw5qCUPDBibl2=	Mln0OFghcA>?		MUHwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36=	NH3jOJYzPDB7OEe5PS=>
SK-N-BE	NVfWR4lpSXCxcITvd4l{KEG\|c3H5	Mny1NQKBmzRyIH7N	NYD3TVB6PDhiaB?=		MX3wc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36=	MX[yOFA6QDd7OR?=
SK-N-AS	NUDlVmpQTnWwY4Tpc44hSXO\|YYm=	MWSw5qCUQDBibl2=	MlywOFghcA>?		M4C1SYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA>	NVrwPVd{OjRyOUi3PVk>
SK-N-DZ	MXnGeY5kfGmxbjDBd5NigQ>?	NY\Gdlc{OOLCk{iwJI5O	M{TrO\|Q5KGh?		MV;pcoR2[2W\|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG\|ZTCzJIFv\CCSQWLQ	NW\hVZdEOjRyOUi3PVk>
SK-N-SH	NFzyUYZHfW6ldHnvckBCe3OjeR?=	MkLBNQKBmzRyIH7N	MYG0PEBp		Mmr3bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=>	MWCyOFA6QDd7OR?=
SK-N-BE	MXXGeY5kfGmxbjDBd5NigQ>?	MlrkNQKBmzRyIH7N	NVfTNIRqPDhiaB?=		MkLKbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=>	NIr6T4gzPDB7OEe5PS=>
HCC-LM3	NXmxbIltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUmxMVExODBibl2=	MoDBNlQwPDhxN{KgbC=>	NEDCPItFVVOR	M2G0V4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NF;3cXUzPDB7M{m1Oi=>
HepG2	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX[xMVExODBibl2=	NGnJRWQzPC92OD:3NkBp	NYnzd49PTE2VTx?=	MVvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M{[4[VI1ODl\|OUW2
SMMC-7721	NETzV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3aXpgyNTFyMECgcm0>	MXSyOE81QC95MjDo	MkK2SG1UVw>?	M4fZOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NVmyO\|JVOjRyOUO5OVY>
HCC-LM3	NXfLN5JwSXCxcITvd4l{KEG\|c3H5	M{n4R\|UxKG6P	MVK0PEBp	M{TOPGROW09?	NXzVeYpTcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG\|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl?	M4TybFI1ODl\|OUW2
HepG2	NYG0fmc3SXCxcITvd4l{KEG\|c3H5	MlPROVAhdk1?	M4XpfFQ5KGh?	M1zUVGROW09?	MmfrbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk>	MWSyOFA6Ozl3Nh?=
SMMC-7721	NHi4NI1CeG:ydH;zbZMhSXO\|YYm=	MmHiOVAhdk1?	MmTxOFghcA>?	MlfhSG1UVw>?	NHPwO\|RqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMhOyxiODDhcoQhQQ>?	NY\XN2NHOjRyOUO5OVY>
HCC-LM3	Ml;nSpVv[3Srb36gRZN{[Xl?	MnvjOVAwOTByIH7N	MnLTNlQhcA>?	MUXEUXNQ	NHTWNFFl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR\|IHHu[EBxNUGtdNMg	M1LOO\|I1ODl\|OUW2
HepG2	MmTqSpVv[3Srb36gRZN{[Xl?	MX61NE8yODBibl2=	NGnEcJQzPCCq	NHK1e\|RFVVOR	MX7k[YNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi	MU[yOFA6Ozl3Nh?=
SMMC-7721	Mk\0SpVv[3Srb36gRZN{[Xl?	MXW1NE8yODBibl2=	NWm4S\|l7OjRiaB?=	NGG5UphFVVOR	MXLk[YNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi	NYf4[G5OOjRyOUO5OVY>
HCC-LM3	M3HWOmZ2dmO2aX;uJGF{e2G7	M4TadVUxNzFyMDDuUS=>	M4[xN\|I1KGh?	NH:y[lFFVVOR	MnT6[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>?	M4rOOlI1ODl\|OUW2
HepG2	NFLBNHJHfW6ldHnvckBCe3OjeR?=	M3H0VVUxNzFyMDDuUS=>	NWDVSHhJOjRiaB?=	M{LjW2ROW09?	NYPme3o5\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?=	MUeyOFA6Ozl3Nh?=
SMMC-7721	M1nuZmZ2dmO2aX;uJGF{e2G7	M1rOZVUxNzFyMDDuUS=>	MoSzNlQhcA>?	M1LINGROW09?	NVSySm1[\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?=	M{fGU\|I1ODl\|OUW2
FaDu	M4DvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF[1c2QyODEkgJXuUS=>	MUi4M\|ExNzF{IHi=		Ml2z[Il{eGyjeXXkJIEhe2mpbnnmbYNidnRiYX7kJJBzd2yxbnfl[EBIOi:PIHHydoV{fCCjdDC4JIFv\CBzMvMAiYgheG:\|dDDy[Yxm[XOn	M1T2WVI1ODJ4NEiy
FaDu	NHHuWW5HfW6ldHnvckBCe3OjeR?=	MnLrNVAx6oDHbl2=	NFi2dGIzNzRxOD:xNkBp		NX[2VVZpcW6mdXPl[EBxOjGZYX[xM2NqeDIEoHX4dJJme3Orb36=	NXLjeGd{OjRyMk[0PFI>
PC-3	M3KzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofxNE0yOCEQvF2=	MYCyOE81QC95MjDo		NFvKRXpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NELz[4wzOzl7MUKxOi=>
LNCaP	NXThb5I1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TtRlAuPSEQvF2=	M3zhUlI1NzR6L{eyJIg>		NXLq[IdDcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MkjCNlM6QTF{MU[=
RWPE-1	NFnSXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{WyNFAuOjBizszN	MojNNlQwPDhxN{KgbC=>		NV;6XlhrcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M{fYN\|I{QTlzMkG2
Capan-1	M3yy[WZ2dmO2aX;uJGF{e2G7	NFnEb2EzPS93MD:xNFAhdk1?	MlrUPE8zPC92ODDo	MVrEUXNQ	NFzrOo1ld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n	MVqyN\|kzOjh6Nh?=
L3.6pl	M13lVmZ2dmO2aX;uJGF{e2G7	MknXNlUwPTBxMUCwJI5O	M2PYVlgwOjRxNEigbC=>	M4X5SWROW09?	NVHXcIlp\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=>	MmDNNlM6OjJ6OE[=
CFPAC-1	NEfjT\|VHfW6ldHnvckBCe3OjeR?=	NHm5[3czPS93MD:xNFAhdk1?	NF7PboY5NzJ2L{S4JIg>	NGi0VIJFVVOR	MYDkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p	MYSyN\|kzOjh6Nh?=
Capan-1	M{DPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXKyOU82OC9zMECgcm0>	MkLmOFghcA>?	NFq3U2pFVVOR	M2\ufZJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MVOyN\|kzOjh6Nh?=
L3.6pl	Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDPc3QzPS93MD:xNFAhdk1?	M2XIblQ5KGh?	NUm4N5BHTE2VTx?=	NEjIOpFz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NF\QToczOzl{Mki4Oi=>
CFPAC-1	MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUP5UYR5OjVxNUCvNVAxKG6P	M{L4cVQ5KGh?	NWDZb3pXTE2VTx?=	NVjhVII5emWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M1;KelI{QTJ{OEi2
Capan-1	NY\RVnVoSXCxcITvd4l{KEG\|c3H5	Mlr1NlUwPTBxMUCwJI5O	NUDJbYN[PDhiaB?=	MXvEUXNQ	NGjr[VVqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MoPmNlM6OjJ6OE[=
L3.6pl	MnHyRZBweHSxc3nzJGF{e2G7	MV:yOU82OC9zMECgcm0>	M{fsO\|Q5KGh?	NFi0eVlFVVOR	Mmn6bY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MXmyN\|kzOjh6Nh?=
CFPAC-1	NUfUV5NwSXCxcITvd4l{KEG\|c3H5	M2X3bFI2NzVyL{GwNEBvVQ>?	M4f6WVQ5KGh?	MV\EUXNQ	M2PDd4lv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NUj0TopbOjN7MkK4PFY>
HN22	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzhdHMxNTJyIH7N	MXuyOE81QCCq	NI\1UI5FVVOR	NEmxdlJqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz	Mn;1NlM5Pzd{M{W=
HSC4	MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnifm04OC1{MDDuUS=>	MY[yOE81QCCq	MmH3SG1UVw>?	NWLvW4tpcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>?	NVuxdplwOjN6N{eyN\|U>
HN22	M1vu[mFxd3C2b4Ppd{BCe3OjeR?=	MYSwMVIxKG6P	MmLJOFghcA>?	NIXMWmVFVVOR	NITFb41qdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MYiyN\|g4PzJ\|NR?=
HSC4	NEHSPVZCeG:ydH;zbZMhSXO\|YYm=	NH3i[Y4xNTJyIH7N	NYLzSYM{PDhiaB?=	MoToSG1UVw>?	MXvpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MU[yN\|g4PzJ\|NR?=
HN22	MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nqUFAuOjBibl2=	MoDROFghcA>?	NXfBVpRpTE2VTx?=	M4r2cIlv\HWlZYOgS\|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=>	MlPWNlM5Pzd{M{W=
HSC4	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHizdGQxNTJyIH7N	M{HqdFQ5KGh?	M{X3RmROW09?	NEj6bIFqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA>	Mor0NlM5Pzd{M{W=
HN22	MYXGeY5kfGmxbjDBd5NigQ>?	NIjaRW4xNTJyIH7N	MoTJOFghcA>?	M3\oXGROW09?	M1fQTpN2eHC{ZYPz[ZMhW3BzIHX4dJJme3Orb39CpC=>	NUTjbGdWOjN6N{eyN\|U>
HSC4	Ml:5SpVv[3Srb36gRZN{[Xl?	M2\o[FAuOjBibl2=	M3P3UlQ5KGh?	MYHEUXNQ	NVjqO\|FQe3WycILld5NmeyCVcEGg[ZhxemW\|c3nvcuKh	NVnyVZZVOjN6N{eyN\|U>
Cal62	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\2TWM2OD1\|MzFCtUA1KG6P	M2nlVVI{QDJ2ME[0
Hth7	MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjjdVVKSzVyPUG1JOKyKDJibl2=	MX[yN\|gzPDB4NB?=
Hth83	M{PJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PMUWlEPTB;M{SgxtEhPSCwTR?=	NEPacokzOzh{NEC2OC=>
C643	M2jTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIq0b3BKSzVyPUexJOKyKDFyIH7N	M1X1V\|I{QDJ2ME[0
SW1736	M{fOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTN3INMxJFghdk1?	NW\aS4VlOjN6MkSwOlQ>
T241	MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTZ3INMxJFchdk1?	NGjk[2czOzh{NEC2OC=>
T351	Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVS5NFdWUUN3ME21NEDDuSBzMDDuUS=>	NGDBNZUzOzh{NEC2OC=>
BHP2-7	M{D6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fsfWlEPTB;M{egxtEhPiCwTR?=	M3G0d\|I{QDJ2ME[0
T238	Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTTZnJKSzVyPUGsOVAxKMLzIEKwNEBvVQ>?	M331RVI{QDJ2ME[0
HCT8	M4rDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWXyeW5lPzJiaB?=	NF7mbm5FVVOR	NVy4[lZ6UUN3ME2xNk466oDLwsJihKkyNjlibl2=	MV6yN\|I6QTN6OB?=
H630	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmDmO\|IhcA>?	M37kXWROW09?	MmL3TWM2OD1zMj605qCKyrIkgJmzMlEhdk1?	M{K0TFI{Ojl7M{i4
cH630 5-FU-res	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{nQOFczKGh?	NVjDZZpRTE2VTx?=	M{XQOGlEPTB;MUWuOgKBkcLz4pEJNU4zKG6P	MnPhNlMzQTl\|OEi=
HCT116	NE\2[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX;6VpRMPzJiaB?=	MYPEUXNQ	NXix[lE{UUN3ME2xNE446oDLwsJihKkzNjJibl2=	M3TZdFI{Ojl7M{i4
HCT116 p53−/−	NUDYOmp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF7FZVg4OiCq	M2\JfmROW09?	MYXJR\|UxRThwNvMAjeKy6oDLMT63JI5O	M3W1OlI{Ojl7M{i4
dHCT116 p21−/−	NEToWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGm3SG04OiCq	MUXEUXNQ	Mlz4TWM2OD13LkpihKnDueLCiUGuN{BvVQ>?	MVuyN\|I6QTN6OB?=
HT29	NWq4[I5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1\sTFczKGh?	MWTEUXNQ	MYLJR\|UxRTF4LkRihKnDueLCiUKuN{BvVQ>?	NV7oUIZ5OjN{OUmzPFg>
LoVo	Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{f0SFczKGh?	MnPQSG1UVw>?	MkTzTWM2OD13LkJihKnDueLCiUCuOkBvVQ>?	NV3qZ3lxOjN{OUmzPFg>
RKO	NFn5bnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoTNO\|IhcA>?	Ml64SG1UVw>?	M{HjcWlEPTB;Nz655qCKyrIkgJmyMlIhdk1?	NEXWPFQzOzJ7OUO4PC=>
SW480	M3[zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Moq4O\|IhcA>?	MXzEUXNQ	MX7JR\|UxRTF5LkZihKnDueLCiUCuPEBvVQ>?	M1PDO\|I{Ojl7M{i4
eSW620	M1f3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX3VZ\|ZXPzJiaB?=	MojFSG1UVw>?	NE\GeJhKSzVyPUmuNgKBkcLz4pEJNk4yKG6P	MoPFNlMzQTl\|OEi=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 / EZH2; PubMed: 19279403 Cancer Biol Ther Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control. caspase-8 / cleaved caspase-8 / Sp1; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. c-Myc / IRF4; PubMed: 27738323 Oncotarget RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting. Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; PubMed: 28915627 Oncotarget Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1. RAD51 / BRCA1 / CHK1 / RPL13a; PubMed: 24244429 PLoS One CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells. H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; PubMed: 31071955 Int J Mol Sci Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.	19279403 27738323 28915627 24244429 31071955
Immunofluorescence	Synaptophysin / NACM; PubMed: 28915627 Oncotarget Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm. α-tubulin / Acetyl-α-tubulin; PubMed: 29983882 Oncotarget CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm. BiP; PubMed: 23544167 Transl Oncol Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. ATF4; PubMed: 23544167 Transl Oncol HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. IRE1α / S724-IRE1α; PubMed: 23544167 Transl Oncol Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.	28915627 29983882 23544167
Growth inhibition assay	Cell viability; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.	27738323

In vivo

In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. ^[2]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
Concentrations: 50 nM
Incubation Time: 48 hours
Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 10⁴ cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
(Only for Reference)

Animal Research:^[2]

- Collapse

Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (10⁷ cells) or A549 (5 × 10⁶ cells), H69 (2.5 × 10⁶ cells), BK-T (6.5 × 10⁶), H526 (10 × 10⁶), and RG1 (10 × 10⁶) cells
Dosages: 10 mg/kg, 20 mg/kg
Administration: Administered via i.p. injection
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	69 mg/mL (197.46 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+48% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Panobinostat (LBH589) SDF

Molecular Weight	349.43
Formula	C₂₁H₂₃N₃O₂
CAS No.	404950-80-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NVP-LBH589
Smiles	CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04341311	Recruiting	Drug: Marizomib\|Drug: Panobinostat	Diffuse Intrinsic Pontine Glioma\|Pediatric Brainstem Glioma\|Pediatric Brainstem Gliosarcoma Recurrent\|Pediatric Cancer\|Pediatric Brain Tumor\|Diffuse Glioma	Dana-Farber Cancer Institute\|Celgene\|Secura Bio	August 10 2020	Phase 1
NCT03632317	Withdrawn	Drug: Panobinostat\|Drug: Everolimus	Glioma\|Diffuse Intrinsic Pontine Glioma	University of Michigan Rogel Cancer Center	October 2019	Phase 2
NCT03982134	Withdrawn	Drug: PDR001\|Drug: Panobinostat	Melanoma\|Non Small Cell Lung Cancer	Muhammad Furqan\|Novartis Pharmaceuticals\|University of Iowa	September 2019	Phase 1
NCT04326764	Recruiting	Drug: Panobinostat	Acute Myeloid Leukaemia (AML)\|Myelodysplastic Syndromes (MDS)	Goethe University\|Jan J. Cornelissen (HOVON-SAKK)\|Sebastian Giebel (PALG)	July 24 2018	Phase 3
NCT03515915	Unknown status	--	Patients With Recurrent or Refractory Multiple Myeloma	University Hospital Montpellier\|Poitiers University Hospital	April 23 2018	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to reconstitute the compound for in vivo mice study?
Answer:
We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA for cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Panobinostat (LBH589)